BRGX — BioRegenx Balance Sheet
0.000.00%
- $7.38m
- $9.53m
- $1.85m
Annual balance sheet for BioRegenx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.024 | 0.001 | 0.125 | 0.058 | 0.069 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | — | 0.105 | 0.015 | 0.04 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.024 | 0.001 | 0.653 | 0.308 | 0.251 |
| Net Property, Plant And Equipment | — | — | 0.014 | 0.201 | 0.16 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 0.128 | 0.059 | 0.866 | 0.509 | 0.411 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.014 | 0.065 | 2.79 | 3.63 | 4.07 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.212 | 0.261 | 2.94 | 3.89 | 4.95 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.084 | -0.202 | -2.07 | -3.38 | -4.54 |
| Total Liabilities & Shareholders' Equity | 0.128 | 0.059 | 0.866 | 0.509 | 0.411 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |